Digital twins – the convergence point for AI-enabled personalised healthcare and next-generation deep learning

AI-driven biotech and healthcare signal a new wave of technological convergence that is already rewriting business strategy. The UK, like many European peers, must navigate the complex landscape of funding availability, innovation, and value creation. Here, we examine how the government and industry can seize emerging opportunities in biopharma and healthcare, how these opportunities look, and what the UK can learn from comparable European efforts.

The escalating cost of bringing new therapeutics to market and persistent attrition rates have intensified the search for new R&D* frameworks. These pressures extend into the clinic, where improved patient stratification and therapy matching remain unaddressed1-5. Despite major advances in deep learning/AI, current methods still depend on static analytical architectures and limited live biological feedback1. At the same time, we lack in silico-to-in vitro-to-in vivo continuum for truly effective healthcare solutions – those that personalize care, identify and prevent adverse drug reactions, and optimize treatment strategies1-3. Beyond diagnostics and drug development, therapy and healthcare process management is emerging as a crucial domain requiring specialized monitoring, cross-system integration, and the capacity for continuous self-updating. Its deployment will necessarily be accompanied by rigorous regulatory and ethical oversight.

Addressing these gaps presents both economic opportunities and a need for unconventional approaches capable of capturing dynamic processes across preclinical and clinical domains. Digital twins (DTs) have emerged as the key convergence point for this shift–offering the technological dynamism required for next-generation biopharma and healthcare. They also provide a strategic platform on which the UK can build competitive advantage and deepen high‑value partnerships across Europe (e.g., European Virtual Human Twins (VHT) Initiative and Apply AI Strategy).

Economic Landscape & Motivation. There is a very clear economic incentive for these new technological advancements6-8(Fig. 1), as the DT market is estimated to reach $48.2B globally in 20266. The global digital healthcare market, which is closely tied to AI and DT-enabled solutions, such as wearables or telemonitoring, was valued at $180.2B in 2023 and is projected to reach $549.7B by 2028, achieving a CAGR* of 25% from 2023 to 20287. These fast developing markets accentuate the need for better healthcare enabling technologies and greater diversity among developers, particularly as the US continues to lead investments in research8. As the UK and Europe’s sectors are underinvested, this creates a widening gap between technological potential and market readiness. Only through bold investment strategies and stronger cross-border collaboration, especially with European initiatives that are already accelerating DT-enabled healthcare (e.g., the EU-funded DTRIP4H project for the development of a decentralized DT ecosystem that enables researchers, innovators and SMEs to devise applications that address specific scientific challenges), can the UK secure a meaningful role in the rapidly expanding global AI and convergent technology market.

Technology Emergence & Impact Building. The discussed economic drivers and the clearer delineation of current bottlenecks highlight that new solutions are both necessary and achievable. To compete globally, the UK must enter these markets with distinctive, high‑value technological propositions that allow it to capture and shape emerging opportunities. We argue that, for AI‑native R&D and personalized healthcare, this advantage can be built by recognising the role of DTs as catalysts for closed‑circuit systems and the advancement of new deep‑learning methodologies–such as adaptive deep learning (ADL)–alongside integrated screening technologies (e.g., lab‑on‑a‑chip, LOC) that enable continuous dataflow and real‑time predictions¹. Our previous work9-13 has demonstrated that these new types of technologies and the new class of AI–ADL capable of adapting to inputs without pre-set schemas1–captures complex data and patterns inaccessible to conventional models. Importantly, DTs unify these systems for continuous feedback, in silico and in vitro adjustments to extract and analyze omics dataflows (Fig. 2). The UK already has necessary foundations to support these breakthrough technologies through the DT ecosystem, namely DTNet+, CVD-NET, and others.

Figure 3. DT-driven closed-loop framework. LOC-derived imaging, sensing & multi-omics data integrate with ADL & in silico tools to support personalised disease modelling.

However, the UK ecosystem needs to have a grounded roadmap - currently there are too many competing interests, prioritising institutional needs. We can also learn from European tried-and-tested strategies aiming to unify data and research (e.g., European Health Data Space Regulation; EHDS). Well-established applied solutions are essential for moving beyond the hype cycle (Fig. 3), especially as many AI-driven initiatives have stalled without delivering meaningful progress. This is evident in the trajectory of several AI companies that once promised AI-discovered drugs but have since shifted toward selling platforms that failed to meet their original drug discovery claims. Importantly, countries parallelising technological advancement with regulatory coordination can expect faster entry to market - again valuable lessons offered by the EU with comprehensive initiatives, such as the Data Act, for fair data access, user rights, and the protection of personal data embedded into economic and funding strategies, allowing companies to address any challenges during the development.

For the UK, the stagnation of the R&D sector and lack of national investment coordination underscores the importance of re-establishing strategic partnerships with Europe to build credible, deployable technologies that deliver real clinical and economic value. Such co-development would not only pool expertise and infrastructure but also create shared, interoperable resources capable of competing with the scale and speed of US and Asian ecosystems. By aligning investment, regulation, and technological development, the UK and Europe can jointly accelerate the transition from hype to impact, securing a stronger position in the next generation of biopharma and healthcare markets.

Figure 3. Algorithmic developments motivating DT, adaptive learning, and closed-loop healthcare innovation. Timeline highlights advances shaping feedback-enabled DTs.

Authors

References

Technology and Innovation programme activities

techUK bring members, industry stakeholders, and UK Government together to champion emerging technologies as an integral part of the UK economy. We help to create an environment where innovation can flourish, helping our members to build relationships, showcase their technology, and grow their business. Visit the programme page here.